Ventana Medical Systems, Inc.

The Cleveland Clinic Foundation

The University of Melbourne

University of California

The United States Government As Represented by the Department of Veterans Affairs

F. Hoffmann-la Roche Ag

Spring Bioscience Corporation

The United States of America As Represented by the Deparment of Vetererans Affairs

Shalini Singh

Michael S Barnes

Crystal Schemp

Fernando Jose Rebelo Do Couto

Thomas M Grogan

Zhiming Liao

Yifei Zhu

Kandavel Shanmugam

Esteban Roberts

Penny Towne

June F Clements

Ting Chen

Srinivas Chukka

Anindya Sarkar

Christophe Chefd'hotel

Fabien Gaire

Hiro Nitta

Alisa Tubbs

Olcay Sertel

Pradipta Ghosh

Bonnie LaFleur

Andrea Muranyi

Raymond Tubbs

Paul Waring

Ulrich-Peter Rohr

Song Hu

Nikolaus Wick

Katherine Leith

Michael Barnes

Paul Michael Waring

Fernando Couto

Christophe CHEFD´HOTEL

James Ranger-Moore

Christophe Chefd´hotel

Edmundo David Del Valle

The invention provides anti-human pro-epiregulin and anti-human amphiregulin antibodies and methods of using the same. Anti-EREG antibodies raised against amino acids 148-169 and 156-169 of the human EREG protein, and anti-AREG antibodies raised against amino acids 238-252 of the human AREG protein are disclosed. Methods of using these antibodies to detect EREG and AREG and kits and other products for performing such methods are also disclosed.

Materials and methods for performing histochemical assays for human pro-epiregulin and amphiregulin

Disclosed herein are methods for identifying a subject as having NSCLC that is predicted or is likely to respond to treatment with an ALK inhibitor, for example crizotinib. The methods include identifying a sample including NSCLC tumor cells as ALK-positive or ALK-negative using immunohistochemistry (IHC) and scoring methods disclosed herein. A subject is identified as having NSCLC likely to respond to treatment with an ALK inhibitor if the sample is identified as ALK-positive and is identified as having NSCLC not likely to respond to treatment with an ALK inhibitor if the sample is identified as ALK-negative. According to certain embodiments of the methods, subjects predicted to respond to an ALK inhibitor may then be treated with an ALK inhibitor such as crizotinib.

Method of identifying treatment responsive non-small cell lung cancer using anaplastic lymphoma kinase (ALK) as a marker

Heterogeneity for biomarkers in a tissue sample can be calculated. A heterogeneity score can be combined with an immunohistochemistry combination score to provide breast cancer recurrence prognosis. Heterogeneity can be based on percent positivity determinations for a plurality of biomarkers according to how many cells in the sample stain positive. An immunohistochemistry combination score can be calculated. An imaging tool can support a digital pathologist workflow that includes designating fields of view in an image of the tissue sample. Based on the fields of view, a heterogeneity metric can be calculated and combined with an immunohistochemistry combination score to generate a breast cancer recurrence prognosis score.

Image analysis for breast cancer prognosis

Described herein are methods for co-expression analysis of multiple markers in a tissue sample comprising: computing a heat map of marker expression for each of a plurality of single marker channel images, wherein each of the plurality of single marker channel images comprise a single marker; identifying one or more candidate regions of interest in each heat map of marker expression; computing overlay masks comprising the identified one or more candidate regions of interest from each heat map of marker expression; determining one or more co-localized regions of interest from the overlay masks; mapping the one or more co-localized regions of interest to a same coordinate position in each of the plurality of single marker channel images; and estimating a number of cells in at least one of the determined one or more co-localized regions of interest in each of the plurality of single marker channel images.

Systems and methods for co-expression analysis in immunoscore computation

Disclosed herein are methods for identifying a subject as having NSCLC that is predicted or is likely to respond to treatment with an ALK inhibitor, for example crizotinib. The methods include identifying a sample including NSCLC tumor cells as ALK-positive or ALK-negative using immunohistochemistry (IBC) and scoring methods disclosed herein. A subject is identified as having NSCLC likely to respond to treatment with an ALK inhibitor if the sample is identified as ALK-positive and is identified as having NSCLC not likely to respond to treatment with an ALK inhibitor if the sample is identified as ALK-negative. According to certain embodiments of the methods, subjects predicted to respond to an ALK inhibitor may then be treated with an ALK inhibitor such as crizotinib.

Growing community of inventors

Tucson, AZ, United States of America

Shalini Singh